| Program | Target | Indication | Radionuclides | Discovery | Lead optimization | IND-enabling | Phase 1 | Phase 2 |
|---|---|---|---|---|---|---|---|---|
| AUR002 | Undisclosed | Solid tumors | ⁶⁸Ga · ¹⁷⁷Lu | reached | current stage | |||
| AUR003 | Undisclosed | Solid tumors | ⁶⁸Ga · ¹⁷⁷Lu | current stage | ||||
| AUR004 | Undisclosed | Solid tumors | ⁶⁸Ga · ¹⁷⁷Lu | current stage | ||||
| AUR005 | Undisclosed | Solid tumors | ⁶⁸Ga · ¹⁷⁷Lu | current stage | ||||
| AUR000 | Alpha platform | Alpha-emitting payload for the peptide ligands | α · undisclosed | current stage | ||||
| Status as of October 2026. No program is approved for use in any country. | ||||||||
Each therapeutic program has a ⁶⁸Ga imaging agent on the same ligand, so no patient is treated without a scan that shows that the target is present and that the ligand reaches it.
An imaging agent is given at a tracer dose, which has no pharmacological effect, to a small number of patients whose tumors are expected to express the target of interest. That scan shows that the target is present, where it is located within the body, and the dose that each organ would receive when given the ¹⁷⁷Lu-labeled therapeutic. Only patients whose scans showed tumor uptake of the imaging agent would proceed to therapy. Because the ligand, chelator, and manufacturing processes are the same between the diagnostic and therapeutic agents, the data from the imaging study apply directly to the therapeutic.
A peptide radioligand in lead optimization.
AUR002 is a peptide radioligand against a solid-tumor antigen which is not yet disclosed. The candidates are being optimized for residence time on the target, selectivity, and clearance ahead of IND-enabling studies. The ⁶⁸Ga imaging agent and the ¹⁷⁷Lu therapy share one scaffold, so the imaging data collected in the first clinical study apply directly to the therapy.
An antibody circulates for days, so a large part of its radiation dose is delivered to healthy organs rather than to the tumor. A peptide of fewer than 40 residues is cleared within hours, penetrates solid tumor tissue which an antibody reaches unevenly, and gives an image that can be read on the day it is given.
An alpha-emitting payload for the peptide ligands.
Some tumors need an alpha emitter: small metastases, and cells which are hypoxic and resistant to the beta particle. An alpha particle deposits its energy within a few cell diameters, so a ligand that reaches the tumor within minutes and is cleared within hours is well matched to it, provided the emitter stays on the ligand in the body. The chemistry which holds the alpha emitter on the peptide is the subject of the platform, and it is not disclosed at this stage.
AUR000 gives the ¹⁷⁷Lu programs an alpha-emitting counterpart on the same ligands, so that a target validated with the beta therapy can be treated with the alpha therapy without a new ligand or a new imaging agent.
Research stage: the payload chemistry is being developed and tested for stability in serum and in animals. The platform is built to be ubiquitous: because it attaches to the same ligands and the same conjugation site, any of the ¹⁷⁷Lu programs can be translated into an alpha program without a new ligand, a new imaging agent, or a new manufacturing process.
No Aurelius trial is recruiting at present. When a trial opens it will be listed on this page, and registered on ClinicalTrials.gov and in the EU Clinical Trials Register before the first patient is enrolled.